Beta Bionics (US.BBNX)
资本配置审计 · 期间： 2022 – 2026
核心指标
US.BBNX · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 106.3% | → |
| ROE | -17.7% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.03 | ↓ |
| Gross Margin | 59.3% | ↑ |
US.BBNX (Beta Bionics) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 106.3% → ROE -17.7% ↓ Cash Conversion - → D/E Ratio 0.03 ↓ Gross Margin 59.3% ↑
核心指标
US.BBNX (Beta Bionics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 106.3% →ROE -17.7% ↓Cash Conversion - →D/E Ratio 0.03 ↓Gross Margin 59.3% ↑免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies